XELPROS

Peak

latanoprost

NDAOPHTHALMICEMULSION
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Prostaglandin Analog

Clinical Trials (5)

NCT07325240Phase 4Active Not Recruiting

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Started Nov 2025
30 enrolled
Open Angle GlaucomaOcular Hypertension
NCT04140279Phase 4Withdrawn

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Started May 2022
0
Ocular Hypertension
NCT04957329Phase 4Recruiting

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Started Sep 2021
NCT03931317N/ACompleted

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

Started Dec 2018
70 enrolled
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
NCT04737928N/ACompleted

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Started Apr 2018
1 enrolled
Glaucoma, Primary Open Angle

Loss of Exclusivity

LOE Date
Sep 12, 2029
42 months away
Patent Expiry
Sep 12, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
9539262
Oct 15, 2028
U-2400
9629852
Sep 12, 2029
Product